Hims & Hers Health (NYSE:HIMS) Upgraded at Zacks Research

Zacks Research upgraded shares of Hims & Hers Health (NYSE:HIMS) from a strong sell rating to a hold rating in a report published on Wednesday morning,Zacks.com reports.

HIMS has been the subject of a number of other research reports. BTIG Research lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday. Morgan Stanley reduced their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday. Truist Financial restated a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday. Bank of America cut their price target on Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research note on Monday, February 9th. Finally, Leerink Partners lowered their price target on Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating for the company in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Reduce” and an average target price of $32.27.

Hims & Hers Health Stock Performance

HIMS opened at $14.51 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.64 and a debt-to-equity ratio of 1.80. The business’s 50 day moving average is $26.60 and its 200-day moving average is $39.18. The stock has a market cap of $3.30 billion, a PE ratio of 28.44, a price-to-earnings-growth ratio of 3.33 and a beta of 2.43. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same period last year, the firm earned $0.11 EPS. The firm’s revenue was up 28.4% compared to the same quarter last year. On average, analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has authorized a share buyback program on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to buy up to 3% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the transaction, the insider directly owned 6,175 shares in the company, valued at approximately $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the sale, the insider directly owned 169,940 shares in the company, valued at $6,238,497.40. This trade represents a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 82,963 shares of company stock valued at $2,944,621 in the last quarter. Insiders own 13.71% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtus Advisers LLC acquired a new position in Hims & Hers Health in the second quarter valued at about $26,000. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the third quarter worth approximately $28,000. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Finally, Bogart Wealth LLC raised its stake in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Company strategy: HIMS is expanding its digital-health platform into labs, cancer screening, menopause care and new international markets — a move that increases addressable market and strengthens its subscription/preventive-care positioning. Hims & Hers Expands Digital Health and Global Platform Strategy
• Positive Sentiment: Long-term growth case: Bullish coverage pieces note HIMS’s digitally native, direct-to-consumer model, growing subscriber base and profitability potential, presenting a recovery/buy case for longer-term investors. Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
• Neutral Sentiment: Analyst sentiment shifting slowly: Zacks moved the stock from “strong sell” to “hold,” a mild positive signal but not a clear upgrade to growth conviction. Zacks Research Upgrade Notice
• Neutral Sentiment: Retail/investor interest: HIMS has been heavily searched and discussed on Zacks/Yahoo — heightened attention can amplify moves in either direction but doesn’t by itself change fundamentals. Investors Heavily Search Hims & Hers Health, Inc. (HIMS)
• Neutral Sentiment: Market action signal: Unusually large options volume has been reported, indicating elevated speculative activity and short-term volatility risk. Hims & Hers Health Sees Unusually Large Options Volume
• Negative Sentiment: Regulatory & legal risk — GLP-1 scrutiny: Novo Nordisk filed a patent suit over compounded weight-loss drugs sold by HIMS; the FDA is investigating the company’s compounded GLP-1 practices and the SEC has opened an inquiry into disclosures on weight-loss products. These developments are the principal near-term driver of downside pressure. Hims Faces GLP-1 Scrutiny While Broader Telehealth Growth Story Evolving
• Negative Sentiment: Analyst downgrades & price-target cuts: BTIG downgraded to Neutral and Citigroup cut its price target to $13.25, prompting further selling pressure and signaling decreased near-term expectations. BTIG Research Downgrades Hims & Hers Health to Neutral
• Negative Sentiment: Shareholder litigation risk: A law firm announced an investigation into the board over disclosures around the decision to stop selling its Wegovy-like product, adding governance/legal overhang. Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.